• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A Response to: Letter to the Editor Regarding "Real-World Effectiveness of a Third Dose of mRNA-1273 Versus BNT162b2 on Inpatient and Medically Attended COVID-19 Among Immunocompromised US Adults".

作者信息

Georgieva Mihaela, Sun Tianyu, Beck Ekkehard

机构信息

Moderna, Inc., 325 Binney Street, Cambridge, MA, 02142, USA.

出版信息

Infect Dis Ther. 2024 Nov;13(11):2457-2459. doi: 10.1007/s40121-024-01039-5. Epub 2024 Sep 18.

DOI:10.1007/s40121-024-01039-5
PMID:39289328
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11499559/
Abstract
摘要

相似文献

1
A Response to: Letter to the Editor Regarding "Real-World Effectiveness of a Third Dose of mRNA-1273 Versus BNT162b2 on Inpatient and Medically Attended COVID-19 Among Immunocompromised US Adults".对《致编辑的信：关于美国免疫功能低下成年人中第三剂mRNA-1273与BNT162b2对住院及接受医疗护理的COVID-19的真实世界有效性》的回应
Infect Dis Ther. 2024 Nov;13(11):2457-2459. doi: 10.1007/s40121-024-01039-5. Epub 2024 Sep 18.
2
Real-World Effectiveness of a Third Dose of mRNA-1273 Versus BNT162b2 on Inpatient and Medically Attended COVID-19 Among Immunocompromised US Adults.美国免疫功能低下成年人中，第三剂mRNA-1273与BNT162b2对住院及需就医的新冠肺炎的真实世界有效性
Infect Dis Ther. 2024 Aug;13(8):1771-1787. doi: 10.1007/s40121-024-01005-1. Epub 2024 Jun 25.
3
Letter to the Editor Regarding: "Real-World Effectiveness of a Third Dose of mRNA-1273 Versus BNT162b2 on Inpatient and Medically Attended COVID-19 Among Immunocompromised US Adults".致编辑的信：关于“第三剂mRNA-1273与BNT162b2对美国免疫功能低下成年人住院及需就医的COVID-19的真实世界有效性”
Infect Dis Ther. 2024 Nov;13(11):2455-2456. doi: 10.1007/s40121-024-01038-6. Epub 2024 Sep 18.
4
Real-world comparative effectiveness of mRNA-1273 and BNT162b2 vaccines among immunocompromised adults identified in administrative claims data in the United States.美国行政索赔数据中识别出的免疫功能低下成年人中 mRNA-1273 和 BNT162b2 疫苗的真实世界比较效果。
Vaccine. 2022 Nov 8;40(47):6730-6739. doi: 10.1016/j.vaccine.2022.09.025. Epub 2022 Sep 24.
5
Real-world comparative effectiveness of a third dose of mRNA-1273 versus BNT162b2 among adults aged ≥ 65 years in the United States.美国≥65 岁成年人中 mRNA-1273 第三剂与 BNT162b2 相比的真实世界疗效比较。
Vaccine. 2024 Nov 14;42(25):126113. doi: 10.1016/j.vaccine.2024.07.014. Epub 2024 Jul 18.
6
Relative Effectiveness of BNT162b2, mRNA-1273, and Ad26.COV2.S Vaccines and Homologous Boosting in Preventing COVID-19 in Adults in the US.BNT162b2、mRNA-1273和Ad26.COV2.S疫苗以及同源加强免疫在美国成年人中预防新冠病毒病的相对有效性
Open Forum Infect Dis. 2023 May 25;10(7):ofad288. doi: 10.1093/ofid/ofad288. eCollection 2023 Jul.
7
Comparative effectiveness of mRNA-1273 and BNT162b2 COVID-19 vaccines in immunocompromised individuals: a systematic review and meta-analysis using the GRADE framework.mRNA-1273 与 BNT162b2 新冠疫苗在免疫功能低下人群中的有效性比较：使用 GRADE 框架进行的系统评价和荟萃分析。
Front Immunol. 2023 Sep 12;14:1204831. doi: 10.3389/fimmu.2023.1204831. eCollection 2023.
8
Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case-control study.BNT162b2 BA.4/5 二价 mRNA 疫苗在美国大型医疗体系中针对一系列 COVID-19 结局的有效性：一项病例对照研究。
Lancet Respir Med. 2023 Dec;11(12):1089-1100. doi: 10.1016/S2213-2600(23)00306-5. Epub 2023 Oct 25.
9
Antibody titers after a third dose of the SARS-CoV-2 BNT162b2 vaccine in immunocompromised adults in Greece: Is a fourth dose necessary?希腊免疫功能低下成年人接种第三剂 SARS-CoV-2 BNT162b2 疫苗后的抗体滴度：是否需要接种第四剂？
J Med Virol. 2022 Oct;94(10):5056-5060. doi: 10.1002/jmv.27954. Epub 2022 Jul 1.
10
Effectiveness of COVID-19 vaccines at preventing emergency department or urgent care encounters and hospitalizations among immunocompromised adults: An observational study of real-world data across 10 US states from August-December 2021.COVID-19 疫苗在预防免疫功能低下成年人急诊或紧急护理就诊和住院方面的有效性：2021 年 8 月至 12 月期间在美国 10 个州的真实世界数据的观察性研究。
Vaccine. 2023 Aug 23;41(37):5424-5434. doi: 10.1016/j.vaccine.2023.05.038. Epub 2023 May 22.

本文引用的文献

1
Real-world comparative effectiveness of a third dose of mRNA-1273 versus BNT162b2 among adults aged ≥ 65 years in the United States.美国≥65 岁成年人中 mRNA-1273 第三剂与 BNT162b2 相比的真实世界疗效比较。
Vaccine. 2024 Nov 14;42(25):126113. doi: 10.1016/j.vaccine.2024.07.014. Epub 2024 Jul 18.
2
Real-World Effectiveness of a Third Dose of mRNA-1273 Versus BNT162b2 on Inpatient and Medically Attended COVID-19 Among Immunocompromised US Adults.美国免疫功能低下成年人中，第三剂mRNA-1273与BNT162b2对住院及需就医的新冠肺炎的真实世界有效性
Infect Dis Ther. 2024 Aug;13(8):1771-1787. doi: 10.1007/s40121-024-01005-1. Epub 2024 Jun 25.
3
Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Older Adults: Systematic Literature Review and Meta-Analysis Using the GRADE Framework.mRNA-1273和BNT162b2新冠疫苗在老年人中的比较效果：使用GRADE框架的系统文献综述和荟萃分析
Infect Dis Ther. 2024 Apr;13(4):779-811. doi: 10.1007/s40121-024-00936-z. Epub 2024 Mar 18.
4
Comparative Effectiveness of Bivalent (Original/Omicron BA.4/BA.5) COVID-19 Vaccines in Adults.二价（原始毒株/奥密克戎BA.4/BA.5）新冠疫苗在成人中的比较有效性
Vaccines (Basel). 2023 Nov 11;11(11):1711. doi: 10.3390/vaccines11111711.
5
Relative Effectiveness of BNT162b2, mRNA-1273, and Ad26.COV2.S Vaccines and Homologous Boosting in Preventing COVID-19 in Adults in the US.BNT162b2、mRNA-1273和Ad26.COV2.S疫苗以及同源加强免疫在美国成年人中预防新冠病毒病的相对有效性
Open Forum Infect Dis. 2023 May 25;10(7):ofad288. doi: 10.1093/ofid/ofad288. eCollection 2023 Jul.
6
Exclusion of older adults and immunocompromised individuals in influenza, pneumococcal and COVID-19 vaccine trials before and after the COVID-19 pandemic.在 COVID-19 大流行前后，流感、肺炎球菌和 COVID-19 疫苗试验中排除老年人和免疫功能低下者。
Aging Clin Exp Res. 2023 May;35(5):917-923. doi: 10.1007/s40520-023-02380-4. Epub 2023 Apr 7.
7
Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study.BNT162b2 mRNA COVID-19 疫苗加强针在预防以色列重症结局的有效性：一项观察性研究。
Lancet. 2021 Dec 4;398(10316):2093-2100. doi: 10.1016/S0140-6736(21)02249-2. Epub 2021 Oct 29.
8
Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting.BNT162b2 mRNA 新冠疫苗在全国范围内使用的安全性。
N Engl J Med. 2021 Sep 16;385(12):1078-1090. doi: 10.1056/NEJMoa2110475. Epub 2021 Aug 25.
9
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.mRNA-1273 新型冠状病毒疫苗的有效性和安全性。
N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30.
10
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.BNT162b2 mRNA 新冠病毒疫苗的安全性和有效性。
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.